Rocket Pharma Q3 net loss $50.3M; KRESLADI PDUFA March 2026; Danon trial to resume 1H 2026

ROCKET PHARMACEUTICALS, INC.

2025-Q3 EPS reported -$1.63

Q3 net loss $50.3M ($0.45/share), down from $66.7M ($0.71) YoY; R&D expenses $34.1M vs $42.3M.
Cash, equivalents, investments $222.8M; runway expected into Q2 2027.
FDA accepted KRESLADI (marne-cel) BLA resubmission for severe LAD-I; PDUFA target March 28, 2026.
Phase 2 trial of RP-A501 for Danon disease to resume dosing in 1H 2026 after FDA lifted clinical hold.
Appointed Dr. Syed Rizvi as CMO, Christopher Stevens as COO, Sarbani Chaudhuri as Chief Commercial & Medical Affairs Officer.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.